抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究

抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究

ID:20806778

大小:628.03 KB

页数:42页

时间:2018-10-16

抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究_第1页
抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究_第2页
抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究_第3页
抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究_第4页
抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究_第5页
资源描述:

《抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、授予单位代码10089学号或申请号15145中国图书分类号R743.3HebeiMedicalUniversity硕士学位论文学术学位抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究研究生:刘荣导师:檀国军教授专业:神经病学二级学院:河北医科大学第二医院2018年3月目录中文摘要·········································································································

2、·1英文摘要··········································································································2研究论文抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究前言······································································································

3、····4资料与方法······························································································5结果··········································································································7附表···································

4、·······································································8讨论··········································································································9结论····································································

5、······································15参考文献··································································································15附录·········································································································

6、·18综述急性脑梗塞的免疫相关机制进展·····················································22致谢···············································································································37个人简历··························································

7、··············································38抗栓联合抗炎疗法治疗急性脑梗死患者的临床疗效评价及安全性研究摘要目的:探索抗栓基础上联合小剂量地塞米松的抗炎疗法治疗急性脑梗死患者的临床效果及安全性。方法:将24小时内发病的40例急性脑梗死患者随机分为小量地塞米松组、微小剂量组、微量地塞米松组及对照组。在常规抗栓和他汀治疗(对照组)的基础上分别加用地塞米松1.25mg、2.5mg、5mg(依次为微量地塞米松组、微小量地塞米松组、小量地塞米松组)静脉滴注

8、,每天一次,共7d。各组分别于治疗后的第1天、7天行血常规及血沉检查,于治疗后的第1个月和第3个月采用Barthel指数及Rankin量表对所有脑梗死患者进行神经系统的功能评定。结果:小量组的血沉较微小剂量组、微量组及对照组明显减慢,且差异有显著性(P<0.05),而微小剂量组与微量组及对照组无明显差异。根据Barthel指数及改良的Rankin量表评定结果,小量组的神经功能较微小剂量组、微量组及对照组明显改善,且差异有显著性(P<0.05),而微小剂量组与微量组及对照组无明显差异

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。